1Etemadifar M,Janghorbani M,Shaygannejad V,et al.Comparison of Betaferon,Avonex,and Rebif in treatment of relapsing-remitting multiple sclerosis.Acta Neurol Scand,2006,113:283-287.
2Vartanian T,Solberg Sorensen P,Rice G.Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.J Neurol,2004,251 Suppl 2:Ⅱ25-Ⅱ30.
3Rudick RA,Cutter GR,Baier M,et al.Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients.Mult Scler,2005,11:626-634.
4Tremlett H,Paty D,Devonshire V,et al.Disability progression in multiple sclerosis is slower than previously reported.Neurology,2006,66:172-177.
5Sorensen PS,Fazekas F,Lee M.Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis:a metaanalysis.Eur J Neurol,2002,9:557-563.
6Martinelli Boneschi F,Rovaris M,Johnson KP,et al.Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis:meta-analysis of three double-blind,randomized,placebo-controlled clinical trials.Mult Scler,2003,9:349-355.
7Polman CH,O′Connor PW,Havrdova E,et al.A randomized,placebo-controlled trial of natalizumab for relapsing multiple sclerosis.N Engl J Med,2006,354:899-910.
